-
Mashup Score: 0Combining radiotherapy and immunotherapy in cancer care - 1 year(s) ago
Conflicting clinical results on the benefits of combined radiotherapy and immunotherapy may derive from differences in treatment sequencing
Source: Daily ReporterCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0VJOncology – The video journal of oncology - 1 year(s) ago
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the awareness and understanding of oncology
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0VJOncology – The video journal of oncology - 1 year(s) ago
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the awareness and understanding of oncology
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2European Society for Medical Oncology - 1 year(s) ago
ESMO Congress 2021 – find out more about ESMO’s flagship portfolio and Elsevier’s Oncology Journal Network, and browse our special conference article collections
Source: www.elsevier.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Treatment with dostarlimab (Jemperli) plus chemotherapy reduced the risk of disease progression or death by 30% compared with pembrolizumab (Keytruda) plus chemotherapy as a frontline treatment for patients with metastatic non-squamous non–small cell lung cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2European Society for Medical Oncology - 1 year(s) ago
ESMO Congress 2021 – find out more about ESMO’s flagship portfolio and Elsevier’s Oncology Journal Network, and browse our special conference article collections
Source: www.elsevier.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3cAttendee - 1 year(s) agoSource: cattendee.abstractsonline.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 5Positive results for combination in KRAS G12C-mutated NSCLC - 1 year(s) ago
Phase III trials are planned to assess combined KRAS G12C inhibition/checkpoint inhibition as first-line therapy
Source: Daily ReporterCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 5NSCLC, neoadjuvant camrelizumab plus chemotherapy - 1 year(s) ago
Positive results from a phase II trial adds weight to the value of immunotherapy as neoadjuvant treatment for resectable NSCLC
Source: Daily ReporterCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0ctDNA is prognostic for adjuvant atezolizumab in NSCLC - 1 year(s) ago
Confirmation from an exploratory analysis of IMpower010, however its predictive value is still uncertain
Source: Daily ReporterCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
#ESMOImmuno22: Is combining radiotherapy and immunotherapy a viable treatment option? Conflicting clinical results on the benefits of this approach may derive from differences in treatment sequencing. đź“Śhttps://t.co/FY06BirifU https://t.co/n5tKVqJd6q